louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06967441: Respiratory Virus Infections in Acute Heart Failure
Official title: Respiratory Virus Infections in Hospitalized Patients With Acute Heart Failure Syndrome: A Prospective Multi-center Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Heart Failure Syndrome
Keywords: acute heart failure
respiratory virus
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
Collaborators: name: Samsung Medical Center
name: Seoul St. Mary's Hospital
First posted: 2025-05-13
Enrollment: 360
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalised with AHF at three healthcare facilities who had respiratory virus PCR testing performed

Brief summary: Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort.

The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. The investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection.


Eligibility criteria: Inclusion Criteria:

* Adult aged 19 years or older admitted to the cardiology department with acute heart failure
* NT-proBNP \>300 pg/mL
* Clinician judgement of possible respiratory viral infection (fever \>38 degrees or cough, respiratory symptoms such as sputum or consolidation on x-ray or CRP \>5 mg/dL)
* Patients who have a nasopharyngeal swab for respiratory virus PCR test performed within 72 hours of admission for any of the 3 reasons

Exclusion Criteria:

* Patients with a clear other cause of acute heart failure (ex. STEMI, bradycardia requiring a pacemaker, SBP \>200mmHg or DBP \>110mmHg, haemoglobin \<7g/dL)
* If the cause of pulmonary oedema is prominently attributed to exacerbation of CKD
* If there is a clear other source of infection that can explain the fever

Primary outcomes:
measure: Respiratory virus PCR detection rate
timeFrame: Within 3 days of admission
Secondary outcomes:
measure: Days of hospitalization
timeFrame: From admission to discharge during index hospitalization (upto 30 days)
measure: Rate of ICU care or ventilation
timeFrame: From admission to discharge during index hospitalization (upto 30 days)
measure: In hospital mortality
timeFrame: From admission to discharge during index hospitalization (upto 30 days)
measure: mortality
timeFrame: 12 month
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
city: Seoul
country: Korea, Republic of
facility: Samsung medical center
city: Seoul
country: Korea, Republic of
facility: Seoul ST. Mary's Hospital
Study officials:
References:
Clinical trial NCT06154941: Clinical Evaluation of Giomer Based Varnish Versus CPP-ACP Varnish in the Management of Dentin Hypersensitivity: a Randomized Clinical Trial
Official title: Clinical Evaluation of Giomer Based Varnish Versus CPP-ACP Varnish in the Management of Dentin Hypersensitivity: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Dentin Hypersensitivity
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-12-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dentin hypersensitivity is a drastic problem, which threaten many dental patients. According to the last published systematic review and meta analysis at 2019, the prevalence of dentin hypersensitivity is being 33.5% among the population. Moreover, it was determined that young adults with age range from 18 to 44 years exhibited high percentage (43.9%) of such problem

Detailed description: Several approaches to dentin hypersensitivity treatment were proposed to interfere, whether transiently or permanently, with the hydrodynamic theory. These approaches include root coverage and the use of lasers, ions, dentinal sealants, and occluding and nerve depolarization agents, chosen according to the primary cause. There are two major strategies in managing DH; the first is nerve desensitization, and the second is the physical occlusion of the patent tubule. The second approach can be carried out through a wide range of treatment modalities, including the use of proteins, salts or ions to plug the tubules. Many agents introduced are capable of sealing dentinal tubules, and can be used to reduce sensitivity. Of these agents are CPP-ACP varnish and the newly introduced giomer based varnish wilth S-PRG technology

Eligibility criteria: Inclusion Criteria:

* Participants of both genders aged 18 to 40 years with good oral hygiene, suffering from pain due to dentin hypersensitivity in at least one tooth

Exclusion Criteria:

* Taking desensitizing treatment in the last 6 months. (It affects the outcome)

  * Taking anti-inflammatory drugs. (It affects the hypersensitivity perception)
  * Pregnant females. ( They complain from nausea and repeated vomiting attacks)
  * Smokers. (Smoking will affect the oral hygiene and periodontal health)

Primary outcomes:
measure: evaporative test
timeFrame: Immediately postoperative, after 1,3 and 6 months
measure: Thermal Test
timeFrame: Immediately postoperative, after 1,3 and 6 months
measure: Tactile test
timeFrame: Immediately postoperative, after 1,3 and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry
Study officials:
References:
Clinical trial NCT05286541: Buccal Cortical Separation and Lateralization for Horizontal Ridge Augmentation
Official title: Qualitative and Quantitative Assessment of Autogenous Versus Xenogenic Horizontal Ridge Augmentation After Mandibular Ridge-split with Buccal Cortical Lateralization: a Randomizedcontrolled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Horizontal Ridge Deficiency
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-03-18
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cases with horizontal ridge deficiency less than what is possible for ridge splitting were recruited and the buccal cortex was totally separated and lateralized at the desired distance for augmentation


Eligibility criteria: Inclusion Criteria:

* suffering only from posterior mandibular horizontal ridge deficiency and with adequate inter-arch space to accommodate the future restoration

Exclusion Criteria:

* Heavy smokers, diabetics, patients with bleeding problems, liver and kidney diseases, bone diseases that can affect bone healing, previous history of any ridge augmentation procedure in the posterior mandible, and those undergoing or planned for radiotherapy or chemotherapy

Primary outcomes:
measure: Change in horizontal bone gain
timeFrame: six months after the operation
Secondary outcomes:
measure: Bone area percent
timeFrame: Six months after the operation
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dentistry, Cairo University
Study officials:
affiliation: Associate Professor
name: Mohammed Atef, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02509741: Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China
Official title: Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Keywords: obesity
nutrition
intervention
food replacement
IOT
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2015-07-28
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research is aimed at verifying the effects of diets with high protein and low glycemic index (GI) on weight management among overweight or obese Chinese adult. Additionally, the investigators intend to verify the effects of two new approaches, including food replacement and Internet-of-things (IOT) monitoring on weight control.


Eligibility criteria: Inclusion Criteria:

* Health adult, age:18-65，BMI（kg/m2）:27.0-40.0

Exclusion Criteria:

* Patients under regular medical treatment for chronic diseases like diabetes, hypertension, gout and hyperuricemia.
* The patients with chronic renal diseases or other diseases which impose restrictions on the intake of proteins.
* Mental patients.
* People who suffer from secondary obesity caused by endocrine, metabolic disorders or some central nervous system diseases.
* People who are under medical or surgical weight-loss treatments in the past three months.
* People whose weight fluctuations are not less than 5kg in the past two months；
* People with food allergies.
* Men or women who drink regularly over 25g or 15 g daily,respectively.
* Pregnant women and women who prepare to be pregnant.
* Lactating women

Primary outcomes:
measure: Composite changes of weight, waist circumference and BMI
timeFrame: 3~5 years
measure: Body composition change is measured by means of Bioelectrical Impedance Analysis (BIA) and CT scan
timeFrame: 3~5 years
measure: Dropout ratio during weight-loss period and maintenance period
timeFrame: 3~5 years
Secondary outcomes:
measure: Composite changes in cardiovascular health indicators such as blood pressure, blood glucose, and blood lipids
timeFrame: 3~5 years
measure: Composite changes in inflammatory markers, diet and physical activity level, Leptin and adiponectin, compliance of weight-loss and other indicators
timeFrame: 3~5 years
measure: Composite changes in diet-related behaviors such as satiety, food preferences, social support, appetite, healthy lifestyle and psychological aspects
timeFrame: 3~5 years
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Southwest Hospital
state: Chongqing
city: Hangzhou
country: China
facility: Hangzhou PLA sanatorium
state: Zhejiang
Study officials:
affiliation: Chinese PLA General Hospital
name: Qiang Zeng, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06808841: Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study
Official title: Sufentanil is Paired Via the BMP6/SMAD Pathway Cardiac Injury in Lower Extremity Fracture Surgery Function Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Myocardial Injury
Lead sponsor: Second Hospital of Shanxi Medical University
Sponsor class: OTHER
First posted: 2025-02-05
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. To analyze the association of different doses of opioids on myocardial injury/protection through BMP-6/SMAD pathway.
2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow.
3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.

Detailed description: This study explored the important role of BMP6/SMAD pathway in myocardial/injury protection by observing the effects of different doses of opioids on myocardial injury indexes hs-cTnI and BMP-6 related indexes in patients undergoing lower extremity fracture surgery, as well as the changes of BMP6 expression in bone marrow tissue of fracture end. The relationship between different doses of opioids and BMP6 and cardiac adverse events provides a theoretical basis for clinical rational drug use.

Eligibility criteria: Inclusion Criteria:

* There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture.
* ASA grades I to III, gender is not limited.

Exclusion Criteria:

* Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury.
* Old fracture
* Stroke patients
* Liver cirrhosis, kidney failure
* Serious systemic infections, alcoholism, drug dependence
* Pathological fracture
* Use of glucocorticoids in the past one month
* Diabetic

Primary outcomes:
measure: Serum BMP6
timeFrame: Immediate postoperative measurement
Secondary outcomes:
measure: one marrow tissue BMP6
timeFrame: Immediate postoperative measurement
Other outcomes:
measure: Perioperative cardiac adverse events
timeFrame: Immediate postoperative measurement
Locations:
city: Taiyuan
country: China
facility: Second Hospital of Shanxi Medical University
state: Shanxi
Study officials:
References:
Clinical trial NCT05481541: The Effect of E-Mobile and Written Education
Official title: The Effect of E-Mobile and Written Education on Quality of Life and Sleep After Transurethral Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Quality of Life
Sleep
Education
Counseling
Nursing
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2022-08-01
Enrollment: 83
Sex: MALE
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Bening's Prostate Hyperplasia (BPH), which is closely related to aging, is one of the most common diseases in the world. Although it is not a life-threatening condition, lower urinary tract symptoms (LUTS) are seen in many patients, which disrupts their daily activities, sleep patterns, and quality of life of the patients. Examination of changes in sleep and quality of life after transurethral resection of the prostate (TUR-P) in patients with LUTS due to BPH and planning training according to their needs will positively affect the lives of these patients. It is very important for nurses to provide individual training and counseling by making use of innovative technology to ensure that patients manage the surgical process in a healthy way and cope with possible complications. This thesis study was planned as a three-group randomized controlled experimental study in order to determine the effect of e-mobile training and counseling on quality of life and sleep in patients who underwent TUR-P to manage the operative process and cope with possible complications.

Detailed description: This thesis study aims to determine the effect of e-mobile training and counseling on quality of life and sleep in patients who underwent TUR-P for BPH, to manage the operation process and to cope with possible complications, and to determine the effectiveness of the written training given to the patients, the control group and the e-mobile application designed for comparasion.

Eligibility criteria: Inclusion criteria:

- Being literate, not having communication, hearing and visual impairments, not having any psychiatric disorders, not having sleep apnea, using a smartphone for at least 1 year in the experimental group,

Exclusion Criteria:

-The patient's refusal to participate in the study

Primary outcomes:
measure: 1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [Time Frame: 0 days-3 month]
timeFrame: Time Frame:0-3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Cukurova University
state: Eyalet/Yerleşke
city: Adana
country: Turkey
facility: Cukurova University
Study officials:
affiliation: Cukurova Universty Faculty of Health Sciences Adana, Turkey
name: Sevban Arslan, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04319341: Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia
Official title: Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Antiphospholipid Antibody Syndrome in Pregnancy
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2020-03-24
Enrollment: 513
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an initially pure, non-thrombotic oAPS; included in the NOH-APS cohort; having been followed in Nîmes for their first pregnancy following the diagnosis of oAPS; N=513.

Brief summary: Study based on data concerning the first pregnancy treated and followed up after the diagnosis of oAPS in the NOH-APS cohort, according to clinical results already published; and on a thematic library collected and preserved at the time of the positive pregnancy test.

ADAMTS 13 will be explored in the available samples defined above: ADAMTS13 antigen (presence of the molecule), ADAMTS13 activity (VWF proteolysis activity of the molecule), global autoantibodies against ADAMTS13 (plasma antibodies recognizing solid phase insolubilized ADAMTS13), these 3 parameters for the description of ADAMTS13 being measured using commercially available diagnostic kits, ELISA type, Technozyme® range, Technoclone, Vienna, Austria.

The clinical endpoint evaluated will be the occurrence (yes/no) of preeclampsia, which is assessed globally, all subtypes combined. Then evaluated according to subtype: late preeclampsia from 34 weeks, early preeclampsia before 34 weeks, eclampsia (convulsions), HELLP syndrome, preeclampsia associated with the birth of a small-for-gestational-age child (defined at percentile 10 of the tables adjusted for gestational age and sex; severe: defined at percentile 3), preeclampsia associated with a retro-placental hematoma, ...


Eligibility criteria: Inclusion Criteria:

* Presence of frozen plasma samples from the positive pregnancy test blood sample.
* Adult patients, included in the NOH-APS cohort, who have successfully initiated a new pregnancy after diagnosis of oAPS.

Exclusion Criteria:

* Absence of frozen plasma sample from the blood sample from the positive pregnancy test.
* Patient who objected to the use of their data.

Primary outcomes:
measure: The quantification, in vitro, of the activity of ADAMTS13
timeFrame: at inclusion (J0)
measure: The quantification, in vitro, of ADAMTS13 antigen
timeFrame: at inclusion (J0)
measure: The quantification, in vitro, of ADAMTS13 autoantibodies
timeFrame: at inclusion (J0)
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémea
Study officials:
References:
Clinical trial NCT01168141: Window Study of ZD4054 in Metastatic Prostate Cancer
Official title: Assessment of the Effects of the Specific Endothelin-A Antagonist ZD4054 on Prostate Cancer Biomarkers in Patients With Castrate-resistant Metastatic Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Prostate Cancer
Metastasis
Keywords: Castrate-resistant prostate cancer with bone metastasis
Lead sponsor: The Christie NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2010-07-23
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This is a prospective study in which patients with castrate-resistant prostate cancer and bone metastases will undergo imaging, donate blood, bone marrow and urine samples, and where possible primary tumour and bone metastatic tissue, before and during treatment with ZD4054, an orally active specific endothelin-A antagonist. The samples will be used primarily for biomarker studies, and it is hypothesized that these will inform on the mechanism of action of this drug. Magnetic Resonance Imaging (MRI) will be performed to evaluate emerging functional imaging endpoints as markers of early response in bone metastatic prostate cancer.


Eligibility criteria: Inclusion Criteria:

* histological confirmation of prostate adenocarcinoma
* documented evidence of bone metastasis on bone scan or MRI
* biochemical progression of prostate cancer
* surgically or medically castrate with serum testosterone ≤2.4nmol/L
* ECOG performance status 0 - 2
* life expectancy of 6 months or more.

Exclusion Criteria:

* radiotherapy to bone lesion or prostatic bed within 4 weeks of starting study treatment.
* prior targeted cancer therapies (such as gefitinib, bevacizumab)
* systemic radionuclide therapy within 12 weeks of starting study treatment.
* current therapy, within 4 weeks of study entry with potent inhibitors of CYP3A4 (ketoconazole, itraconazole, ritonavir, indinavir, erythromycin, troleandomycin, clarithromycin, diltiazem and verapamil), inhibitors of CYPs 2D6 and 2C9 (quinidine and fluconazole), and potent P450 inducers (phenytoin, rifampicin, carbamazepine and phenobarbitone)
* definite or suspected personal history or family history of adverse drug reactions, or hypersensitivity to drugs that are endothelin antagonists
* ineligibility for MRI scanning includes standard MRI criteria (for example, metal implants such as cochlear implants, cardiac pacemakers, heart valves, aneurysm clips and metal fragments in eyes) and patients known to be allergic to gadolinium-based MRI contrast agents

Primary outcomes:
measure: Changes in tissue biomarkers
timeFrame: 6 weeks
measure: Changes in blood-borne biomarkers
timeFrame: 12 weeks
measure: Changes in imaging biomarkers
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
Study officials:
References:
Clinical trial NCT01666041: Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertriglyceridemia
Keywords: insulin resistance
Lead sponsor: Gachon University Gil Medical Center
Sponsor class: OTHER
First posted: 2012-08-16
Enrollment: 120
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate


Eligibility criteria: Inclusion Criteria:

* hypertriglyceridemia

Exclusion Criteria:

* moderate or severe hypertension, uncontrolled diabetes (HbA1c \> 9%), nephrotic syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease

Primary outcomes:
measure: flow-mediated dilation
timeFrame: 8 weeks of treatment
Secondary outcomes:
measure: insulin resistance
timeFrame: 8 weeks of treatment
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Gil Medical Center
Study officials:
References: